

# Putting patients at the centre: Advancing care in HR+/HER2- Breast Cancer

Thursday 11th June 2026, 11:45 - 12:45  
Harrogate Convention Centre  
Kings Suite

We would like to personally invite you to this Novartis sponsored symposium to provide important updates on the latest data in HR+/HER2- breast cancer and discuss the implications of this data on the future of breast cancer care and treatment in the UK. This symposium is organised and funded by Novartis.

## Agenda

Time	Session	Speaker
11:45 - 11:50	Welcome and Introductions	Doctor Marina Parton Consultant Medical Oncologist The Royal Marsden NHS Foundation Trust
11:50 - 12:10	KISQALI® (ribociclib) + ET <sup>†</sup> : Broadening outcomes for eligible HR+/HER2- advanced and early breast cancer patients at high risk	Doctor Mukesh Mukesh Consultant Clinical Oncologist East Suffolk and North Essex NHS Foundation Trust
12:10 - 12:20	Case Study in HR+/HER2- early breast cancer	Doctor Marina Parton Consultant Medical Oncologist The Royal Marsden NHS Foundation Trust
12:20 - 12:30	Case Study in HR+/HER2- advanced breast cancer	Doctor Annet Pillai Consultant Medical Oncologist Hull and East Yorkshire NHS Trust
12:30 - 12:45	Questions for the speakers	All



Scan or click the QR code for KISQALI®  
Prescribing Information

### Adverse Events reporting:

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).  
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report) or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

KISQALI® (ribociclib) in combination with an aromatase inhibitor is indicated for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence (see section 5.1 for selection criteria). In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.†

KISQALI® (ribociclib) is indicated for the treatment of women with HR+/HER2- locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with an LHRH agonist.†

†KISQALI is not recommended to be used in combination with tamoxifen.

HER=human epidermal growth factor receptor; HR=hormone receptor; LHRH=luteinising hormone-releasing hormone.